Novavax, Inc. (NASDAQ:NVAX)- Healthcare Stocks Shining Bright on Wall Street: Exelixis, Inc. (NASDAQ:EXEL)

Novavax, Inc. (NASDAQ:NVAX) kept active in under and overvalue discussion, NVAX holds price to book ratio of 7.50 that presents much better indicator to find market price of a share price over its book value of equity for investment valuation. Meanwhile, Novavax is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Novavax, Inc., (NVAX) reported the Company participated in the 4th Annual Guggenheim Boston Healthcare Conference on Tuesday, December 13, 2016 at Intercontinental Boston Hotel, Boston, MA.

Fundament/ News Factor in Focus

The co is presenting price to cash flow as 1.22, the low single digit may indicate stock is undervalued and vise versa. On other hand, keeping in mind stable cash flows but few growth prospects make traders to value lower. The firm has price volatility of 11.03% for a week and 6.78% for a month. Its beta stands at 1.84 times. Narrow down four to firm performance, its weekly performance was 4.65% and monthly performance was -3.57%.

Exelixis, Inc. (NASDAQ:EXEL) runs in leading trade, it declining -1.70% to traded at $16.16. EXEL attains analyst recommendation of 1.50 on scale of 1-5 with week’s performance of -7.80%.  Exelixis, Inc. (EXEL) recently reported that two high-level appointments designed to further strengthen the company’s public affairs and business development capabilities following the launch of its newest medicine, CABOMETYX, earlier this year. Susan Hubbard has joined the company as Executive Vice President of Public Affairs and Investor Relations, and Stefan Krauss, Ph.D. has joined as Vice President of Business Development.

To find out the technical position of EXEL, it holds price to book ratio of 137.00 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach. EXEL is presenting price to cash flow of 14.79 and free cash flow concluded as 17.15.

EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 41.30%, and looking further price to next year’s EPS is 95.90%. While take a short look on price to sales ratio, that was 38.20.


About Richard Avery

He is a capital projects manager and process design engineer at a large-cap company. He has renowned MBA degree. Before joining SWR, he was a freelance writer for renounce tech websites. He is currently studying for CFP exam. Interests: Tech stocks, Economic Markets, Blue-chips.

Leave a Reply

Your email address will not be published. Required fields are marked *